Skip to main content

Table 2 Baseline characteristics of the patient cohort

From: Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates

Parameter

All patients (n = 50)

PH score ≤ 3 (n = 24)

PH score ≥ 4 (n = 26)

P value

Age, Median (IQR)

68 (62 – 73)

70 (65 – 76)

64 (61 – 71)

0.025

Sex, n (%)

   

0.832

 Female

10 (20.0)

4 (16.7)

6 (23.1)

 

 Male

40 (80.0)

20 (83.3)

20 (76.9)

 

Etiology of cirrhosis, n (%)

   

0.816

 Alcohol

19 (38.0)

9 (37.5)

10 (38.5)

 

 Viral

7 (14.0)

2 (8.3)

5 (19.2)

 

 Other

11 (22.0)

6 (25.0)

5 (19.2)

 

 No cirrhosis

13 (26.0)

7 (29.2)

6 (23.1)

 

Child–Pugh stage, n (%)

   

0.266

 A

25 (50.0)

14 (58.3)

11 (42.3)

 

 B

10 (20.0)

3 (12.5)

7 (26.9)

 

 C

2 (4.0)

0

2 (7.7)

 

 No cirrhosis

13 (26.0)

7 (29.2)

6 (23.1)

 

ECOG, n (%)

   

1.000

  ≤ 1

47 (94.0)

23 (95.8)

24 (92.3)

 

 2

3 (6.0)

1 (4.2)

2 (7.7)

 

BCLC stage, n (%)

   

0.797

 B

5 (10.0)

2 (8.3)

3 (11.5)

 

 C

42 (84.0)

21 (87.5)

21 (80.8)

 

 D

3 (6.0)

1 (4.2)

2 (7.7)

 

Portal vein invasion, n (%)

   

0.991

 Yes

26 (52.0)

13 (54.2)

13 (50.0)

 

 No

24 (48.0)

11 (45.8)

13 (50.0)

 

Distant metastasis, n (%)

   

1.000

 Yes

25 (50.0)

12 (50.0)

13 (50.0)

 

 No

25 (50.0)

12 (50.0)

13 (50.0)

 

Focality of the liver lesions, n (%)

   

1.000

 Unifocal

11 (22.0)

6 (25.0)

5 (19.2)

 

 Multifocal

39 (78.0)

18 (75.0)

21 (80.8)

 

Sum of the size of the target lesions, mm, Median (IQR)

83 (51 – 135)

58 (45 – 122)

97 (59 – 149)

0.205

AFP, ng/ml, Median (IQR)

277

(16 – 4485)

84

(12 – 1467)

60

(1240 – 18,359)

0.071

Albumin, g/l, Median (IQR)

30 (27 – 33)

33 (30 – 36)

28 (25 – 30)

 < 0.001

Bilirubin, mg/dl, Median (IQR)

1.5 (0.7 – 2.3)

0.8 (0.6 – 1.7)

2.2 (1.5 – 3.1)

 < 0.001

INR, Median (IQR)

1.2 (1.1 – 1.3)

1.2 (1.1 – 1.4)

1.2 (1.1 – 1.3)

0.984

Creatinine, mg/dl

0.9 (0.7 – 1.1)

0.8 (0.7 – 1.0)

0.9 (0.7 – 1.2)

0.431

Immunotherapeutic agent, n (%)

 atezolizumab + bevacizumab

29 (58.0)

17 (70.8)

12 (46.2)

0.201

 pembrolizumab

11 (22.0)

3 (12.5)

7 (26.9)

 

 nivolumab

10 (20.0)

4 (16.7)

7 (26.9)

 

Line of systemic treatment, n (%)

   

0.107

 First

29 (58.0)

17 (70.8)

12 (46.2)

 

 Second

11 (22.0)

5 (20.8)

6 (23.1)

 

 Third

10 (20.0)

2 (8.3)

8 (30.7)

 

Previous therapy, n (%)

   

0.200

 Yes

42 (84.0)

18 (75.0)

24 (92.3)

 

 No

8 (16.0)

6 (25.0)

2 (7.7)

 
  1. ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, INR International Normalized Ratio